LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

Начало・Списък с акции・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

591.49 0.68

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

566.96

Максимум

592.17

Ключови измерители
By Trading Economics
Приходи	-72M -114M
Продажби	74M 287M
EPS	-4.956
Марж на печалбата	-39.75
Служители	528
EBITDA	-75M -114M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	-4.45% downside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	4.2B 13B
Предишно отваряне	590.81
Предишно затваряне	591.49

Настроения в новините

By Acuity

50%

167 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

263.2 / 277.1 Подкрепа & съпротива

Madrigal Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.11.2025 г., 16:56 ч. UTC

Печалби

Значими двигатели на пазара

Alimentation Couche-Tard Shares Rise as 2Q Same-Store Sales Support Profit Growth

25.11.2025 г., 23:47 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

25.11.2025 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise After Stock Gains on Wall Street -- Market Talk

25.11.2025 г., 22:39 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

25.11.2025 г., 22:39 ч. UTC

Пазарно говорене

Vault Accelerates Exposure to Spot Gold Prices by Six Months -- Market Talk

25.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

25.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

25.11.2025 г., 21:38 ч. UTC

Печалби

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25.11.2025 г., 21:31 ч. UTC

Пазарно говорене

F&P Healthcare's Share Price Jumps on Profit Guidance Upgrade -- Market Talk

25.11.2025 г., 21:27 ч. UTC

Печалби

These Stocks Moved the Most Today: Nvidia, AMD, Alphabet, Abercrombie, Kohl's, Novo Nordisk, Symbotic, and More -- Barrons.com

25.11.2025 г., 21:20 ч. UTC

Печалби

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25.11.2025 г., 21:18 ч. UTC

Печалби

NIO Stock Drops as EV Maker Posts Narrower Loss -- Barrons.com

25.11.2025 г., 21:15 ч. UTC

Печалби

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25.11.2025 г., 20:16 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls as December Contract Expires -- Market Talk

25.11.2025 г., 18:42 ч. UTC

Пазарно говорене

USDA Backs Mexican Retail Expo to Raise Agricultural Exports -- Market Talk

25.11.2025 г., 18:25 ч. UTC

Придобивния, сливания и поглъщания

S&P Global Completes $1.8 Billion Acquisition Of With Intelligence, Strengthening Its Position As A Leader In Private Markets Data & Analytics >SPGI

25.11.2025 г., 17:30 ч. UTC

Пазарно говорене

Mexico Posts Record Foreign Direct Investment for Jan-Sep -- Market Talk

25.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

25.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

25.11.2025 г., 16:33 ч. UTC

Придобивния, сливания и поглъщания

Eni: Financial Details Weren't Disclosed

25.11.2025 г., 16:33 ч. UTC

Придобивния, сливания и поглъщания

Eni: Block OFF-5 Covers an Area of About 17,000 Km Sq. in Water Depths

25.11.2025 г., 16:32 ч. UTC

Придобивния, сливания и поглъщания

Eni: Agreement to Become Effective After Approval of Uruguayan Authorities

25.11.2025 г., 16:31 ч. UTC

Придобивния, сливания и поглъщания

Eni: Acquisition Is for a 50% Share, Operatorship in Exploration Block OFF-5

25.11.2025 г., 16:30 ч. UTC

Придобивния, сливания и поглъщания

Eni Acquires From YPF Shares in the Exploration Block OFF-5 Offshore Uruguay

25.11.2025 г., 16:23 ч. UTC

Печалби

This Robotics Stock Soars 40% on Earnings. Here's Why. -- Barrons.com

25.11.2025 г., 16:12 ч. UTC

Пазарно говорене

Euro Expected to Rise to $1.25 in 2026: Deutsche Bank -- Market Talk

25.11.2025 г., 16:11 ч. UTC

Пазарно говорене

Dollar Could Take One Final Leg Lower in Early 2026 -- Market Talk

25.11.2025 г., 16:10 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

25.11.2025 г., 16:10 ч. UTC

Пазарно говорене

Sterling Could Briefly Rise After Budget -- Market Talk

25.11.2025 г., 16:10 ч. UTC

Пазарно говорене

Oil Extends Losses on Ukraine-Russia Peace Deal Hopes -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Madrigal Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

-4.45% надолу

12-месечна прогноза

Среден 561.73 USD -4.45%

Висок 650 USD

Нисък 445 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Madrigal Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Madrigal Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

263.2 / 277.1Подкрепа & съпротива

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

167 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.